These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32371022)

  • 1. Controversy regarding ACE inhibitors / ARBs in COVID-19.
    Soria Arcos F; Romero Puche A; Vicente Vera T
    Rev Esp Cardiol (Engl Ed); 2020 Jun; 73(6):516. PubMed ID: 32371022
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
    Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
    J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
    [No Abstract]   [Full Text] [Related]  

  • 4. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
    Albini A; Di Guardo G; Noonan DM; Lombardo M
    Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 6. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
    Ciulla MM
    Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
    [No Abstract]   [Full Text] [Related]  

  • 7. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
    Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
    G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 12. EMA advice on renin-angiotensin system medicines during covid-19 pandemic.
    Drug Ther Bull; 2020 Jun; 58(6):85. PubMed ID: 32295811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.
    Wysocki J; Lores E; Ye M; Soler MJ; Batlle D
    J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323
    [No Abstract]   [Full Text] [Related]  

  • 14. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
    Bozkurt B; Kovacs R; Harrington B
    J Card Fail; 2020 May; 26(5):370. PubMed ID: 32439095
    [No Abstract]   [Full Text] [Related]  

  • 15. Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic.
    Speth RC
    J Travel Med; 2020 May; 27(3):. PubMed ID: 32268374
    [No Abstract]   [Full Text] [Related]  

  • 16. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 19. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
    Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
    N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
    Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
    Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.